EP2072032A1 - Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor - Google Patents
Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor Download PDFInfo
- Publication number
- EP2072032A1 EP2072032A1 EP08103332A EP08103332A EP2072032A1 EP 2072032 A1 EP2072032 A1 EP 2072032A1 EP 08103332 A EP08103332 A EP 08103332A EP 08103332 A EP08103332 A EP 08103332A EP 2072032 A1 EP2072032 A1 EP 2072032A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation according
- hyaluronic acid
- glucosamine
- acetyl
- jalu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 27
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 27
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims description 11
- 230000008929 regeneration Effects 0.000 title abstract description 5
- 238000011069 regeneration method Methods 0.000 title abstract description 5
- 230000003834 intracellular effect Effects 0.000 title 1
- 239000002502 liposome Substances 0.000 claims abstract description 49
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 43
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims abstract description 38
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 13
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 13
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 17
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000001540 sodium lactate Substances 0.000 claims description 5
- 229940005581 sodium lactate Drugs 0.000 claims description 5
- 235000011088 sodium lactate Nutrition 0.000 claims description 5
- 229940045635 sodium pyroglutamate Drugs 0.000 claims description 5
- CRPCXAMJWCDHFM-DFWYDOINSA-M sodium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)[C@@H]1CCC(=O)N1 CRPCXAMJWCDHFM-DFWYDOINSA-M 0.000 claims description 5
- 208000032544 Cicatrix Diseases 0.000 claims description 4
- 244000133098 Echinacea angustifolia Species 0.000 claims description 4
- 235000014134 echinacea Nutrition 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 230000037387 scars Effects 0.000 claims description 4
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 claims description 3
- HDYANYHVCAPMJV-LXQIFKJMSA-N UDP-alpha-D-glucuronic acid Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 206010039580 Scar Diseases 0.000 claims description 2
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 claims description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000002435 rhinoplasty Methods 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 30
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 24
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 15
- 238000000265 homogenisation Methods 0.000 description 12
- -1 PhosPho Chemical class 0.000 description 11
- 229910001220 stainless steel Inorganic materials 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- 231100000321 erythema Toxicity 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000037394 skin elasticity Effects 0.000 description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 5
- 229940097043 glucuronic acid Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000037393 skin firmness Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000037067 skin hydration Effects 0.000 description 4
- PIGCSKVALLVWKU-UHFFFAOYSA-N 2-Aminoacridone Chemical compound C1=CC=C2C(=O)C3=CC(N)=CC=C3NC2=C1 PIGCSKVALLVWKU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- MBLBDJOUHNCFQT-KVPKETBZSA-N n-[(2s,3s,4r,5s)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]acetamide Chemical compound CC(=O)N[C@H](C=O)[C@H](O)[C@@H](O)[C@@H](O)CO MBLBDJOUHNCFQT-KVPKETBZSA-N 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 101100515513 Arabidopsis thaliana XI-E gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- ICQRTPLATMRWJI-JLWXJWIASA-M sodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate;hydrate Chemical compound O.[Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O ICQRTPLATMRWJI-JLWXJWIASA-M 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
Definitions
- the present invention relates to a cosmetic method for the regeneration of hyaluronic acid in cells of connective tissues, starting from the hyaluronic acid precursors D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof. More specifically the invention provides a cosmetic composition containing liposomes loaded with D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, in admixture with a physiologically-acceptable carrier.
- WO2006122638 discloses a filler for use in dermocosmetics, containing hyaluronic acid or derivatives thereof structured in phospholipid liposomes.
- WO03000190 and WO03000191 disclose a method for intra-articular delivery of hyaluronic acid encapsulated in liposomes for the treatment of osteoarthritis.
- WO9813024 discloses a pharmaceutical formulation containing a mixture of hyaluronic acid and liposomes.
- the present invention is based on the finding of an effective method for regenerating hyaluronic acid inside the cells by administering, to a subject in need thereof, a liposomal preparation containing separately - i.e. not linked by chemical bond - the hyaluronic acid precursors D-glucuronic acid (GA) and N-acetyl-D-glucosamine (GlcNH2), or derivatives thereof.
- a liposomal preparation containing separately - i.e. not linked by chemical bond - the hyaluronic acid precursors D-glucuronic acid (GA) and N-acetyl-D-glucosamine (GlcNH2), or derivatives thereof.
- the regeneration of hyaluronic acid inside the cells enables rebuilding the connective tissue damaged by age-related degenerative processes.
- Such a regenerative effect is particularly useful in dermatology, especially for the treatment of wrinckles and skin-aging.
- the invention provides a cosmetic preparation containing liposomal vesicles loaded with D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, in admixture with a cosmetically acceptable carrier.
- the term "derivative” indicates an activated form of D-glucuronic acid and N-acetyl-D-glucosamine, preferably the uridindiphospho-derivatives UDP-D-glucuronic acid and UDP-N-acetyl-D-glucosamine.
- the two active ingredients can be loaded in the same liposomal vesicles or a mixture of vesicles encapsulating either one or the other active ingredient can be used in accordance with the invention.
- the composition may also contain other ingredients that facilitate the regeneration of hyaluronic acid inside the cells, e.g. by inhibiting its degradation by hyaluronidase.
- the hyaluronidase inhibitor is an extract of echinacea angustifolia.
- the liposomal vesicles may be unilamellar (SUV) or multilamellar (MLV) vesicles of various size (small, medium, large, giant), and may be formed by phospholipids or sphingolipids, preferably by phosphatidylcholine; the vesicles can also contain ingredients modulating their resistance, viscosity or stability.
- SUV unilamellar
- MLV multilamellar
- vesicles of various size small, medium, large, giant
- phospholipids or sphingolipids preferably by phosphatidylcholine
- the vesicles can also contain ingredients modulating their resistance, viscosity or stability.
- the phospholipids may be added to a mixture of the two components, or separately to each single component dissolved in a suitable medium, under constant stirring, followed by turbine homogenization.
- the active components are separately added to liposomal vesicles, these are subsequently mixed to form a liposomal mixture of both active ingredients.
- the liposomes can be dispersed in a cosmetic base or preparation, to form a cream, emulsion, microemulsion, ointment, gel, lotion and oil.
- the liposomal preparation is dispersed in a cosmetic base containing water and glycerol, prefarably in the presence of additional ingredients such as EDTA, sodium pyroglutamate, sodium lactate, xanthan gum or similar thickening agents, under conditions suitable for forming a gel paste.
- additional ingredients such as EDTA, sodium pyroglutamate, sodium lactate, xanthan gum or similar thickening agents, under conditions suitable for forming a gel paste.
- the invention provides the use of the compositions herein disclosed for dermatological treatments, particularly for the treatment of unaesthetisms such as wrinckles, skin folds, acne scars, post-injury scars, rhinoplasty scars, lips or face (checks and chin) lift.
- unaesthetisms such as wrinckles, skin folds, acne scars, post-injury scars, rhinoplasty scars, lips or face (checks and chin) lift.
- the invention provides a method for regenerating hyaluronic acid in human cells and tissues, which comprises applying a liposome preparation as above described, onto said cells or tissues.
- Example 1 Preparation of phosphatidylcholine-based liposomal systems for the delivery of D-glucuronic acid (GA) and N-acetyl-D-glucosamine (GlcNH2) and analysis of the content of active ingredients
- Phosphatidylcholine used PhosPho LCN-DS, soy lecithin, minimum 62% purity, Fancor; Egg phosphatidylcholine (PC), XI-E type, 99% purity, Sigma.
- D-glucuronic acid sodium salt monohydrate N-acetyl-L-glucosamine, Aldrich; Cholesterol, Carlo Erba.
- Liposomes were prepared with two methods to increase the encapsulation of AG and GlcNH2.
- Liposome batches were produced using both phosphatidycholine PhosPhs LCN-DS and PC. Also in this case 'placebo' and 'loaded' batches were produced, according to the following procedure:
- Table 2 reports the liposome batches produced with method B Table 2 Batches Phosphatidylcholine (mg) Hydrophilic phase Active ingredient concentration ( ⁇ mol/ml) JALU 43-45 PhosPho LCNDS (15 mg) GA 1 mg 4.3 JALU 46-48 PC (10 mg) GA 1 mg 4.3 JALU 49 PC (10 mg) Water - JALU 62 PhosPho LCNDS (15 mg) Water - JALU 53-55 Phospho LCNDS 15 mg GA 5 mg 21
- a dimensional analysis of the liposome systems was carried out using the laser diffraction apparatus Mastersizer 2000 (Malvern), which operates in a size interval ranging from 20nm to 2mm.
- the apparatus is equipped with a dispersion unit connected to a pump to shake the sample during the analysis.
- Each sample was analysed in triplicate and the results are expressed as d 10 , d 50 and d 90 , i.e. the diameter of 10%, 50% and 90% of the analysed sample.
- Table 3 reports the analysis carried out on placebo batches at different concentrations of phosphatidylcholine, prepared according to each method.
- Table 3 Batch Amount of phosphatidylcholine D 10% ( ⁇ m) D 50% ( ⁇ m) D 90% ( ⁇ m) JALU 8-10 PhosPho LCNDS 7 mg 1.199 5.443 52.251 JALU 14-16 PhosPho LCNDS 15 mg 1.598 8.766 52.908 JALU 20-22 PhosPho LCNDS 60 mg 1.612 26.459 102.922 JALU 49** PC (10 mg) 2.639 6.359 14.602 JALU 62** PhosPho LCNDS (15 mg) 2.903 14.162 47.823 ** indicate the batches prepared with method B
- Phase A Liposome formation
- Example 5 set up of a cellular system for the in vitro evaluation of the liposome systems
- Samples were inoculated according to the following scheme, in sterile conditions and under laminar-flow at 37°C placing 2 ml medium in each well and the wells were incubated at 37°C for 60 hrs, 5% CO2, 97% humidity.
- the pellet was completely dried and digested with 100 mU/ml hyaluronidase SD at 37°C for 1 h and with 100 mU/ml Condroitinase ABC at 37°C for 3 h.
- the samples were then liophilized and derivatized with 2-aminoacridone (AMAC).
- AMAC 2-aminoacridone
- Figure 1 shows that the disaccharide band, which is indicative of hyaluronic acid synthesis, is present in samples containing liposomes and results particularly thicker, which means that a higher concentration of hyaluronic acid is formed, in the samples containing a higher concentration of GA and GlcNH2 precursors.
- the electrophoresis shows that the samples treated with phospholipid concentrations of 15 and 60 mg/ml do not present inhibitory effect on the biosynthesis of hyaluronic acid.
- NHDF Normal Human Dermal Fibroblasts
- Samples were inoculated in sterile conditions, at 37°C with 2 ml medium added to each well and incubated at 37° for 48 or 72 hours, 5% CO2, 97% humidity. 12 hrs after the inoculum, fresh medium was added.
- hyaluronic acid produced by cells is carried out on the medium treated with specific enzymes (hyaluronidase and condroitinase) by means of a chromatographic analysis specific for proteins (FPLC).
- FPLC chromatographic analysis specific for proteins
- the separation is carried out on a pre-packed column Superdex 200HR 10/30 at room temperature, with a flow rate of 0.35 ml/min; ammonium acetate 0.1M pH7, containing 0.05% Tween 20 was used as the buffer.
- the UV-Vis detector was set at 280 nm.
- HA% determined as the ratio of the amount of HA found in cells treated with liposomes to the amount produced by control cells.
- Example 7 in vivo efficacy study using non-invasive methods for cutaneous bioengineering
- Formulation A glucuronic acid 0.1%, acetyl glucosamine 1.1%, phosphoLCN-DS 1.5%, EDTA 2Na 0.5%, glycerol 8%, PCA Na 1%, Na lactate 1%, Sepiplus 400 2.3%, demineralized water q.s. to 100.
- Formulation B used as placebo: phospho LCN-DS 1.5%, EDTA 2Na 0.5%, glycerol 8%, PCA Na 1%, Na lactate 1%, Sepiplus 400 2.3%, demineralized water q.s. to 100.
- the following parameters were considered in this study: water content of horny layer, cutaneous firmness (R0), total (R2) and neat elasticity (R5), erythema degree, skin-feeling.
- the measurement of cutaneous parameters was carried out at the beginning of the experiment (t0) and after 15 (t1), 30 (t2) and 60 (t3) days by means of the multi-probe Cutometer® MPA 580 (CK electronic GmbH, G.F. Secchi, CO), according to the international guidelines.
- erythema indexes i.e. as ratio between the erythema level at time t and the basic erythema level for every site examined.
- the erythema indexes keep close to unit for all times taken into consideration: the application of the two formulations does not cause a change of the erythema level even after a prolonged application.
- both the formulations used in this study are well tolerated and no irritation can be ascribed to the vehicle, to liposomes or to the active ingredients at the studied concentrations.
- Table 4 reports the average hydration values of the population under exam obtained with a corneometer as well as the change with respect to the forearm used as control at each time.
- Table 4 Formulations T 15days T 30days T 60days Formulation A average ⁇ s.d. 43.74 ⁇ 7.62 47.52 ⁇ 9.70 44.09 ⁇ 7.10 % vs. (+34.05) (+38.18) (+28.96) control
- Formulation B average ⁇ s.d. 46.47 ⁇ 7.4 43.18 ⁇ 5.15 44.25 ⁇ 6.94 % vs. (+35.88) (+22.88) (+24.08) control
- Figure 8 reports the variation of the R0 index with respect to the starting value, for both tested formulations, in treated and control areas.
- Figure 9 shows the percent variation of indexes R2 and R5 compared to the non-treated area, for both the tested formulations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to a cosmetic method for the regeneration of hyaluronic acid in cells of connective tissues, starting from the hyaluronic acid precursors D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof. More specifically the invention provides a cosmetic composition containing liposomes loaded with D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, in admixture with a physiologically-acceptable carrier.
- The use of liposomes for the delivery of hyaluronic acid is described in several patent documents. To cite a few examples,
WO2006122638 discloses a filler for use in dermocosmetics, containing hyaluronic acid or derivatives thereof structured in phospholipid liposomes.WO03000190 WO03000191 WO9813024 - The present invention is based on the finding of an effective method for regenerating hyaluronic acid inside the cells by administering, to a subject in need thereof, a liposomal preparation containing separately - i.e. not linked by chemical bond - the hyaluronic acid precursors D-glucuronic acid (GA) and N-acetyl-D-glucosamine (GlcNH2), or derivatives thereof. The regeneration of hyaluronic acid inside the cells enables rebuilding the connective tissue damaged by age-related degenerative processes. Such a regenerative effect is particularly useful in dermatology, especially for the treatment of wrinckles and skin-aging.
- Accordingly, in a first embodiment the invention provides a cosmetic preparation containing liposomal vesicles loaded with D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, in admixture with a cosmetically acceptable carrier. As used herein, the term "derivative" indicates an activated form of D-glucuronic acid and N-acetyl-D-glucosamine, preferably the uridindiphospho-derivatives UDP-D-glucuronic acid and UDP-N-acetyl-D-glucosamine. The two active ingredients (GA and GIcNH2 or their derivatives) can be loaded in the same liposomal vesicles or a mixture of vesicles encapsulating either one or the other active ingredient can be used in accordance with the invention. The composition may also contain other ingredients that facilitate the regeneration of hyaluronic acid inside the cells, e.g. by inhibiting its degradation by hyaluronidase. Preferably the hyaluronidase inhibitor is an extract of echinacea angustifolia.
- The liposomal vesicles may be unilamellar (SUV) or multilamellar (MLV) vesicles of various size (small, medium, large, giant), and may be formed by phospholipids or sphingolipids, preferably by phosphatidylcholine; the vesicles can also contain ingredients modulating their resistance, viscosity or stability.
- Methods known in the art can be used to load liposome vesicles with D-glucuronic acid and/or N-acetyl-D-glucosamine or derivatives thereof; for example, the phospholipids may be added to a mixture of the two components, or separately to each single component dissolved in a suitable medium, under constant stirring, followed by turbine homogenization. In cases where the active components are separately added to liposomal vesicles, these are subsequently mixed to form a liposomal mixture of both active ingredients. Once the process is terminated, the liposomes can be dispersed in a cosmetic base or preparation, to form a cream, emulsion, microemulsion, ointment, gel, lotion and oil.
- In a preferred embodiment, the liposomal preparation is dispersed in a cosmetic base containing water and glycerol, prefarably in the presence of additional ingredients such as EDTA, sodium pyroglutamate, sodium lactate, xanthan gum or similar thickening agents, under conditions suitable for forming a gel paste.
- In a further embodiment the invention provides the use of the compositions herein disclosed for dermatological treatments, particularly for the treatment of unaesthetisms such as wrinckles, skin folds, acne scars, post-injury scars, rhinoplasty scars, lips or face (checks and chin) lift.
- In a further embodiment the invention provides a method for regenerating hyaluronic acid in human cells and tissues, which comprises applying a liposome preparation as above described, onto said cells or tissues.
-
- PAGEFS electrophoresis of cell cultures; the arrow indicates the disaccharide band corresponding to hyaluronic acid;
- S: disaccharide solution indicative of hyaluronic acid;
- A-B: control plates;
- C: plate treated with
placebo liposomes 15 mg/ml; - D: plate treated with
placebo liposomes 60 mg/ml; - E-F: plates treated with liposomes loaded with GA and GlcNH2 at 0.5 and 10 mM concentrations, respectively;
- G-H: plates treated with liposomes loaded with GA and GlcNH2 at 5
e 50 mM concentrations, respectively. - Example 1 - Preparation of phosphatidylcholine-based liposomal systems for the delivery of D-glucuronic acid (GA) and N-acetyl-D-glucosamine (GlcNH2) and analysis of the content of active ingredients
- Phosphatidylcholine used: PhosPho LCN-DS, soy lecithin, minimum 62% purity, Fancor; Egg phosphatidylcholine (PC), XI-E type, 99% purity, Sigma.
- D-glucuronic acid sodium salt monohydrate, N-acetyl-L-glucosamine, Aldrich; Cholesterol, Carlo Erba.
- Liposomes were prepared with two methods to increase the encapsulation of AG and GlcNH2.
- The following variables were introduced:
- preparation method (direct hydration or hydration after forming a lipidic film)
- quantity and type of phosphatidylcholine
- use of cholesterol
- concentrations of GA and GlcNH2 solutions
- The following procedure was followed for 'placebo' and 'loaded' batches:
- weigh the lipophilic phase and add the hydrophilic phase (final volume from 200 µl to 1 ml);
- pass in a vortex until complete phospholipid dispersion and subsequently in termomixer for 15 min at 25°C, 1400 rpm;
- in certain cases maintain the dispersion at 4°C for 24 hrs;
- centrifuge the samples for 60 min at 4°C, 16400 rpm to eliminate the active ingredient that was not encapsulated;
- separate the surnatant from the pellet and maintain the two parts separately freezed at -20°C for subsequent specific dosage of the active ingredients.
- By this method, batches formed by phosphatidylcholine PhosPho LCN-DS were produced; the composition of these batches is reported in Table 1. Unless otherwise specified, the hydrophilic phase volume was maintained at 1 ml. Batches marked with * were hydrated for 24 hrs in a refrigerator prior to centrifugation.
Table 1 Batch Phosphatidylcholine amount Hydrophilic phase Active ingredient concentration (µmol/ml) JALU 3.7 70 mg Water - JALU 20-22 60 mg Water - JALU 35 600 mg Water (10 ml) - JALU 42 15 mg Water (200 µl) - JALU 14-16 15 mg Water - JALU 8-10 7 mg Water - JALU 4-6 70 mg GA 1.5 mg 6.4 JALU 23-25 60 mg GA 0.3 mg 1.3 JALU 17-19 15 mg GA 0.3 mg 1.3 JALU 11-13 7 mg GA 0.3 mg 1.3 JALU 36-38 15 mg GA 1 mg 4.3 JALU 39-41 15 mg GA 1 mg (200 pl) 21.5 JALU 56-58 15 mg GA 5 mg (200 µl) 105 JALU 63 75 mg GA 25 mg 105 JALU 32-34 60 mg GlcNH2 0.3 mg 1.35 JALU 29-31 15 mg GlcNH2 0.3 mg 1.35 JALU 26-28 7 mg GlcNH2 0.3 mg 1.35 JALU 50-52 15 mg GlcNH2 5 mg 22.6 JALU 59-61 15 mg GlcNH2 5 mg (200 µl) 113 JALU 64-66* 15 mg GA 5 mg (200 µl) 105 JALU 67-69* 30 mg GA 5 mg (200 µl) 105 JALU 71-73* 15 mg GlcNH2 5 mg (200 µl) 113 JALU 74-76* 30 mg GlcNH2 5 mg (200 µl) 113 JALU 77-79* 15 mg GlcNH2 10 mg (400 µl) 226 - Liposome batches were produced using both phosphatidycholine PhosPhs LCN-DS and PC. Also in this case 'placebo' and 'loaded' batches were produced, according to the following procedure:
- weigh phosphatidylcholine in a round-bottomed flask
- add 500 µl CHCl3 containing 10 mg/ml cholesterol
- dry in rotavapor under reduced pressure at 40°C for 10 min
- rehydrate with 1 ml hydrophilic phase
- vortex for 10 min, centrifuge for 60 min at 4°C, 16400 rpm
- separate surnatant and pellet and freeze at -20°C.
- Table 2 reports the liposome batches produced with method B
Table 2 Batches Phosphatidylcholine (mg) Hydrophilic phase Active ingredient concentration (µmol/ml) JALU 43-45 PhosPho LCNDS (15 mg) GA 1 mg4.3 JALU 46-48 PC (10 mg) GA 1 mg4.3 JALU 49 PC (10 mg) Water - JALU 62 PhosPho LCNDS (15 mg) Water - JALU 53-55 Phospho LCNDS 15mg GA 5 mg 21 - A dimensional analysis of the liposome systems was carried out using the laser diffraction apparatus Mastersizer 2000 (Malvern), which operates in a size interval ranging from 20nm to 2mm. The apparatus is equipped with a dispersion unit connected to a pump to shake the sample during the analysis. Each sample was analysed in triplicate and the results are expressed as d10, d50 and d90, i.e. the diameter of 10%, 50% and 90% of the analysed sample.
- Table 3 reports the analysis carried out on placebo batches at different concentrations of phosphatidylcholine, prepared according to each method.
Table 3 Batch Amount of phosphatidylcholine D10% (µm) D50% (µm) D90% (µm) JALU 8-10 PhosPho LCNDS 7 mg 1.199 5.443 52.251 JALU 14-16 PhosPho LCNDS 15 mg1.598 8.766 52.908 JALU 20-22 PhosPho LCNDS 60 mg1.612 26.459 102.922 JALU 49** PC (10 mg) 2.639 6.359 14.602 JALU 62** PhosPho LCNDS (15 mg) 2.903 14.162 47.823 ** indicate the batches prepared with method B - The results evidence the formation of vesicles of micrometric size; as far as PhosPho LCNDS is concerned, the size is constant using either of the two methods with the same amount of phospholipids; the results of sample Jalu 49 indicate that the size depends on the purity of the starting phospholipid.
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 56.400%
- GA 0.100%
- GlcNH2 1.100%
the components are mixed until a complete dissolution is obtained. Phase A' is added slowly under turbine (2.500 rounds/min): - LECITHIN 1.500%
homogenization is carried out for 15 min. The turbine is stopped and mixing is continued with the paddle agitator for additional 10 min. - In a separate steel reactor equipped with heating, stirring and turbine, the following solution is prepared:
- DEMINERALIZED WATER 30.000%
- DISODIUM EDTA 0.500%
- GLYCEROL 8.000%
- SODIUM PYROGLUTAMATE 1.000%
- SODIUM LACTATE 1.000%
the solution is shaken until it becomes homogeneous and the mass is heated at 70°C, then Phase B' is added slowly under the turbine (1.500 rounds/min): - XANTHAN GUM 0.400%
homogenization is carried out until complete dispersion of xanthan gum with formation of a compact and homogeneous gel. The mixture is cooled to 25°C and the Phase A is poured under stirring. Stirring is continued for additional 20 min until a homogeneous and compact mass is obtained. - The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- GLUCURONIC ACID 0.100%
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- N-ACETYL-L-GLUCOSAMINE 1.100%
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- Echinacea angustifolia (dry extract) 0.200%
- In an inox-steel reactor equipped with agitator, the three phases A, A' and A" are mixed slowly for 10 min until complete homogenization is obtained.
- In an inox-steel reactor equipped with heating, stirring and turbine the following solution is prepared:
- DEMINERALIZED WATER 29.800%
- DISODIUM EDTA 0.500%
- GLYCEROL 8.000%
- SODIUM PYROGLUTAMATE 1.000 %
- SODIUM LACTATE 1.000%
- The mixture is stirred up to homogeneity and heated at 70°C. Once the temperature is reached, Phase B' is added slowly under turbine (1.500 rounds/min):
- XANTHAN GUM 0.400%
- Homogenization is continued until the dispersion of Xanthan gum is complete and a homogeneous and compact gel is obtained. The temperature is cooled to 25°C and the mass is added to the liposome preparation under stirring. Stirring is continued for 20 min until a homogeneous and compact mass is obtained.
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- UDP - D-GLUCURONIC ACID 0.100%
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- UDP-N-ACETYL-L-GLUCOSAMINE 1.100%
- The following components are exactly weighed and placed in a inox-steel reactor equipped with a variable-speed turbine (0-3000 rounds/min) and with a paddle agitator, in the order:
- DEMINERALIZED WATER 18.800%
- Echinacea angustifolia (dry extract) 0.200%
- In an inox-steel reactor equipped with agitator, the three phases A, A' and A" are mixed slowly for 10 min until complete homogeneity is obtained.
- In an inox-steel reactor equipped with heating, stirring and turbine the following solution is prepared:
- DEMINERALIZED WATER 29.800%
- DISODIUM EDTA 0.500%
- GLYCEROL 8.000%
- SODIUM PYROGLUTAMATE 1.000%
- SODIUM LACTATE 1.000%
- The mixture is stirred up to homogeneity and heated at 70°C. Once the temperature is reached, Phase B' is added slowly under turbine (1.500 rounds/min):
- XANTHAN GUM 0.400%
- Homogenization is continued until the dispersion of Xanthan gum is complete and a homogeneous and compact gel is obtained. The temperature is cooled to 25°C and the mass is added to the liposome preparation under stirring. Stirring is continued for 20 min until a homogeneous and compact mass is obtained.
- Example 5 - set up of a cellular system for the in vitro evaluation of the liposome systems
- The studies on the cellular effects were carried out with NHDF cells (Normal Human Dermal Fibroblasts), 6 passages in DMEM, 10% FBS, 1% PenStrep, 1% glutamine, in multiwell plates (growth area for single well = 9.6 cm2). Each well contained 300,000 confluent cells.
- Samples were inoculated according to the following scheme, in sterile conditions and under laminar-flow at 37°C placing 2 ml medium in each well and the wells were incubated at 37°C for 60 hrs, 5% CO2, 97% humidity.
- Scheme of the samples inoculated in 8 plates:
- ➢ A-B control plate;
- ➢ C plate treated with liposomes (control) 15 mg/ml;
- ➢ D plate treated with liposomes (control) 60 mg/ml;
- ➢ E-F plates treated with liposomes loaded with GA and GlcNH2 at 0.5 and 10 mM concentrations, respectively.
- ➢ G-H plates treated with liposomes loaded with GA and GlcNH2 at 5 and 50 mM concentrations, respectively.
- At the end of the scheduled time period, plates were analysed with phase-contrast optical microscopy, whereby cell death was found in plates D, E, F, G, H. Surnatants were recovered, centrifuged and examined for their hyaluronic acid content. In brief, 1 ml clarified medium was liophilized, taken up with 300 ml ammonium acetate pH 7.0 and precipitated with 4 volumes of cold ethanol and left at -20°C for 16-18 hrs, centrifuged and the pellet was recovered; this step was repeated a second time. At the end of the second precipitation, the pellet was completely dried and digested with 100 mU/ml hyaluronidase SD at 37°C for 1 h and with 100 mU/ml Condroitinase ABC at 37°C for 3 h. The samples were then liophilized and derivatized with 2-aminoacridone (AMAC).
- 40 µl aliquots of 12.5 mM AMAC solution in acetic acid/DMSO (3:17, v/v) were added to each sample and incubated for 10-15 min at room temperature; then 40 µl of 1.25 M NaBH3CN fresh solution were added and the samples incubated for 16-18 hrs at 37°C. After the derivatization, the samples were separated by PAGEFS.
-
Figure 1 shows that the disaccharide band, which is indicative of hyaluronic acid synthesis, is present in samples containing liposomes and results particularly thicker, which means that a higher concentration of hyaluronic acid is formed, in the samples containing a higher concentration of GA and GlcNH2 precursors. - In
Figure 2 the results are expressed as % hyaluronic acid production with respect to the control, assumed 100%. - The incubation time in this experiment (60 hrs) resulted too long for cell survival.
- The electrophoresis shows that the samples treated with phospholipid concentrations of 15 and 60 mg/ml do not present inhibitory effect on the biosynthesis of hyaluronic acid.
- The inoculum of liposomes containing GA and GlcNH2 at 5 and 50 mM concentrations, respectively, induce an increase of the disaccharide band which is indicative of hyaluronic acid synthesis.
- Based on the previous results, the following method was carried out: NHDF (Normal Human Dermal Fibroblasts) cells, 6 passages in DMEM, 10% FBS, 1% PenStrept, 1% glutamine, in
multiwell 6 plates (growth area for each single well = 9.6 cm2). Each well was loaded with 300.000 confluent cells. - Samples were inoculated in sterile conditions, at 37°C with 2 ml medium added to each well and incubated at 37° for 48 or 72 hours, 5% CO2, 97% humidity. 12 hrs after the inoculum, fresh medium was added.
- Samples inoculated in 12 plates:
- 2 control plates 48hr;
- B-C plates treated for 48 hrs with liposomes loaded with GA and GlcNH2 at 0.25 and 5 mM concentrations, respectively;
- H-I plates treated for 48 hrs with liposomes loaded with GA and GlcNH2 at 0.5 and 10 mM concentrations, respectively;
- 2 control plates 72 hrs;
- D-E plates treated for 48 hrs with liposomes loaded with GA and GlcNH2 at 0.25 and 5 mM concentrations, respectively;
- F-G plates treated for 48 hrs with liposomes loaded with GA and GlcNH2 at 0.5 and 10 mM concentrations, respectively.
- At the end of the scheduled time period, plates were analysed with phase-contrast optical microscopy and living cells were counted.
- The analysis of hyaluronic acid produced by cells is carried out on the medium treated with specific enzymes (hyaluronidase and condroitinase) by means of a chromatographic analysis specific for proteins (FPLC). The separation is carried out on a pre-packed
column Superdex 200HR 10/30 at room temperature, with a flow rate of 0.35 ml/min; ammonium acetate 0.1M pH7, containing 0.05% Tween 20 was used as the buffer. The UV-Vis detector was set at 280 nm. - The results for cell viability, expressed as percentage of vital cells compared to controls, are reported in
Figure 3 . Particularly positive results were obtained with plates B-C and D-E wherein viability resulted higher than 80%. - The results in terms of production of hyaluronic acid at 48 and 72 hrs are reported in
Figure 4 . The results are expressed as HA% determined as the ratio of the amount of HA found in cells treated with liposomes to the amount produced by control cells. - The results demonstrate that the production of hyaluronic acid is by far higher in treated plates than in controls; this indicates that the liposomal systems effectively deliver the two hyaluronic acid precursors into fibroblasts, leading to the (re)constitution of this essential component of derma structure and skin.
- Example 7 - in vivo efficacy study using non-invasive methods for cutaneous bioengineering
- Population: 20 healthy volunteers (males and females) were selected on the basis of the following general exclusion criteria:
- individuals presenting, in the investigated cutaneous area, signs that could interfere with the assay results; hypersensitivity or intolerance known for cosmetic products and/or products for body cleaning/detersion, including sunscreens; sun-exposure susceptibility; subjects treated with photosensitive drugs less than one month earlier; individuals treated with UVA and/or UVB radiations less than one month earlier.
- Formulation A: glucuronic acid 0.1%, acetyl glucosamine 1.1%, phosphoLCN-DS 1.5%, EDTA 2Na 0.5%,
glycerol 8%,PCA Na 1%, Na lactate 1%,Sepiplus 400 2.3%, demineralized water q.s. to 100. - Formulation B, used as placebo: phospho LCN-DS 1.5%, EDTA 2Na 0.5%,
glycerol 8%,PCA Na 1%, Na lactate 1%,Sepiplus 400 2.3%, demineralized water q.s. to 100. - The subjects, divided in groups A and B, were requested to apply the formulation A or B, respectively, to the left forearm, whereas right forearms were used as controls.
- The formulations were applied once a day
- The following parameters were considered in this study: water content of horny layer, cutaneous firmness (R0), total (R2) and neat elasticity (R5), erythema degree, skin-feeling. The measurement of cutaneous parameters was carried out at the beginning of the experiment (t0) and after 15 (t1), 30 (t2) and 60 (t3) days by means of the multi-probe Cutometer® MPA 580 (CK electronic GmbH, G.F. Secchi, CO), according to the international guidelines.
- The subjects were adviced not to apply other cosmetic products to the treated areas, 3 days in advance and during the period of study, to avoid uncertain results.
- In order to ascertain the tolerability of the applied formulations on skin, the erythema level on the treated and control sites was evaluated, for all the time periods checked during the study. It is known that an increase of the erythema level following the application of a formulation indicates scarce tolerability of the formulation itself.
- The results obtained in this study are herein reported as erythema indexes, i.e. as ratio between the erythema level at time t and the basic erythema level for every site examined.
- When comparing the histogram referred to the application site with the control (
Figure 5 ) for each time period, no significant differences may be noted; therefore, no increase of the erythema level may be associated to the application of the two formulations. - Further, when observing the graphs obtained for each formulation in time, it is noted that the erythema indexes keep close to unit for all times taken into consideration: the application of the two formulations does not cause a change of the erythema level even after a prolonged application.
- Therefore, both the formulations used in this study are well tolerated and no irritation can be ascribed to the vehicle, to liposomes or to the active ingredients at the studied concentrations.
- The table 4 below reports the average hydration values of the population under exam obtained with a corneometer as well as the change with respect to the forearm used as control at each time.
Table 4 Formulations T15days T30days T60days Formulation A average ± s.d. 43.74±7.62 47.52±9.70 44.09±7.10 % vs. (+34.05) (+38.18) (+28.96) control Formulation B average ± s.d. 46.47±7.4 43.18±5.15 44.25±6.94 % vs. (+35.88) (+22.88) (+24.08) control - By comparing the corneometry values from forearms treated with the corresponding controls, it is noted that the significant increase appears very similar after 15 days application (34.05% and 35.88%). From the above data, it is evident that the application of both formulations is accompanied by an increase of water content in the corneal layer, wherein such hydration improvement can be ascribed to the composition of the formulations and to the presence of liposomes, regardless of the active ingredients contained therein.
- Following repeated applications of formulation A for 30 days, an increase is obtained 66.87% higher than the increase due to the application of formulation B. The greater increase of surface hydration after repeated application of formulation A is probably due to the presence of active ingredients inside liposomes.
- Such hydration increase in subjects belonging to group A is not maintained as such after 60 days daily application (28.96% vs. 24.08% of group B). This result may be due to a stability problem of the active ingredients contained in the liposomal structures.
- The study results are reported in
Figure 6 as hydration indexes, i.e. as ratio between the values obtained at different times t and the basal values (T0). - Even by comparing the results with the basal values, skin hydration increase following application of the formulations may be observed at all times evaluated in this study.
- Skin elasticity and firmness change after application of the formulations is assayed by means of a software programmed to carry out a number of operations with curves obtained after measuring the analyzed area. Exemplary curves obtained during the study are reported in
Figure 7 . - The following, internationally-approved parameters for the evaluation of elasticity and firmness, may be obtained from such curves:
- R0 = highest point of the first curve; skin firmness index;
- R2 = curve portion comprised between the maximum width and the skin ability to re-deform. This parameter is very important since it indicates the total skin elasticity.
- R5 = This parameter indicates the actual elasticity, that is the total elasticity minus the skin viscoelastic portion.
- The results relating to this three parameters will be discussed separately.
- As to skin firmness,
Figure 8 reports the variation of the R0 index with respect to the starting value, for both tested formulations, in treated and control areas. - The results show that after 15 days treatment, both formulations have a definitively higher index with respect to the non-treated areas, showing a clear improvement in skin firmness; after 30 or more days treatment, the improvement is evident only for formulation A, which contains the active ingredients.
- These results are perfectly consistent with the results relating to skin hydration.
- As to skin elasticity parameters,
Figure 9 shows the percent variation of indexes R2 and R5 compared to the non-treated area, for both the tested formulations. - The results are in line with those reported above: after 15 days treatment, a positive effect due to the application of formulations containing liposomes may be observed whereas, in case the application is prolonged, the specific action of glucuronic acid and of glucosamine contained in liposome systems may result in a consistent increase of skin elasticity.
-
- 1. lyposomes containing glucuronic acid and acetyl-glucosamine have suitable characteristics of size and active-ingredients content.
- 2. the in vitro results clearly show an increase in the amount of hyaluronic acid produced by cells after incubation of the precursor-containing liposomes, thus pointing out the ability of liposomal systems to deliver active ingredients inside fibroblasts.
- 3. the formulation containing glucuronic acid and acetyl-glucosamine proved well-tolerated after a continued two-month use; such formulation proved also capable to remarkably improve skin hydration, firmness and elasticity parameters after 30 days treatment with respect to the formulation containing placebo liposomes.
Claims (11)
- A cosmetic preparation containing liposome vesicles loaded with D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, in admixture with a cosmetically-acceptable carrier.
- A preparation according to claim 1, wherein said derivatives are selected from UDP-D-glucuronic acid and UDP-N-acetyl-D-glucosamine.
- A preparation according to claims 1-2, further containing a hyaluronidase inhibitor.
- A preparation according to claim 3, wherein said hyaluronidase inhibitor is an extract of echinacea angustifolia.
- A preparation according to claims 1-4, wherein the vesicles consist essentially of phosphatidylcholine.
- A preparation according to claims 1-4, which is in the form of cream, emulsion, microemulsion, ointment, gel, lotion or oil.
- A preparation according to claim 6, which is in the form of a gel containing water and glycerol.
- A preparation according to claim 7, further containing EDTA, sodium pyroglutamate, sodium lactate and a thickening agent, preferably xanthan gum.
- The use of liposomes encapsulating D-glucuronic acid and N-acetyl-D-glucosamine, or derivatives thereof, for the preparation of a cosmetic composition.
- The use of a preparation according to claims 1-8, for the cosmetic treatment of wrinckles, skin folds, acne scars, post-injury scars, rhinoplasty scars, lips or face (checks and chin) lift.
- A method for regenerating hyaluronic acid in human cells or tissues, which comprises applying a preparation according to claims 1-8 onto said cells or tissues.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20072348 ITMI20072348A1 (en) | 2007-12-17 | 2007-12-17 | METHOD FOR CELL RIGENERATION OF HYALURONIC ACID AND ITS COSMETIC COMPOSITION |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2072032A1 true EP2072032A1 (en) | 2009-06-24 |
EP2072032B1 EP2072032B1 (en) | 2012-06-20 |
Family
ID=39627773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20080103332 Active EP2072032B1 (en) | 2007-12-17 | 2008-04-02 | Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2072032B1 (en) |
ES (1) | ES2389788T3 (en) |
IT (1) | ITMI20072348A1 (en) |
WO (1) | WO2009077094A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011074059A (en) * | 2009-09-03 | 2011-04-14 | Nagase Chemtex Corp | Agent for increasing quantity of hyaluronic acid |
WO2017178415A1 (en) * | 2016-04-11 | 2017-10-19 | Libragen | Skin restoration product |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295092A2 (en) * | 1987-06-12 | 1988-12-14 | Unilever Plc | Skin treatment composition |
WO1995024497A2 (en) * | 1994-03-11 | 1995-09-14 | Fidia Advanced Biopolymers S.R.L. | Enzymatic preparation of polysaccharides |
WO1998013024A2 (en) | 1996-09-27 | 1998-04-02 | Hyal Pharmaceutical Corporation | Hyaluronic drug delivery system |
WO2003000190A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
WO2003000191A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
WO2006122638A1 (en) | 2005-05-20 | 2006-11-23 | Fidia Farmaceutici S.P.A. | Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
-
2007
- 2007-12-17 IT ITMI20072348 patent/ITMI20072348A1/en unknown
-
2008
- 2008-04-02 EP EP20080103332 patent/EP2072032B1/en active Active
- 2008-04-02 ES ES08103332T patent/ES2389788T3/en active Active
- 2008-12-05 WO PCT/EP2008/010348 patent/WO2009077094A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295092A2 (en) * | 1987-06-12 | 1988-12-14 | Unilever Plc | Skin treatment composition |
WO1995024497A2 (en) * | 1994-03-11 | 1995-09-14 | Fidia Advanced Biopolymers S.R.L. | Enzymatic preparation of polysaccharides |
WO1998013024A2 (en) | 1996-09-27 | 1998-04-02 | Hyal Pharmaceutical Corporation | Hyaluronic drug delivery system |
WO2003000190A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
WO2003000191A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
WO2006122638A1 (en) | 2005-05-20 | 2006-11-23 | Fidia Farmaceutici S.P.A. | Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011074059A (en) * | 2009-09-03 | 2011-04-14 | Nagase Chemtex Corp | Agent for increasing quantity of hyaluronic acid |
WO2017178415A1 (en) * | 2016-04-11 | 2017-10-19 | Libragen | Skin restoration product |
CN108883047A (en) * | 2016-04-11 | 2018-11-23 | 奇华顿股份有限公司 | Skin repair product |
US11026875B2 (en) | 2016-04-11 | 2021-06-08 | Givaudan S.A. | Skin restoration product |
CN108883047B (en) * | 2016-04-11 | 2021-10-01 | 奇华顿股份有限公司 | Skin repair product |
Also Published As
Publication number | Publication date |
---|---|
EP2072032B1 (en) | 2012-06-20 |
WO2009077094A1 (en) | 2009-06-25 |
ITMI20072348A1 (en) | 2009-06-18 |
ES2389788T3 (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6227856B2 (en) | Composition and method for skin care | |
JP5191988B2 (en) | Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same | |
CN112891241A (en) | Targeted mitochondrial skin anti-aging nano composition and preparation method and application thereof | |
KR101851388B1 (en) | Composition for enhancing percutaneous absorption of ginsenosides, manufacturing method thereof and cosmetic preparations for hair growth | |
JP3128215B2 (en) | Bradykinin antagonist consisting of Rosaceae extract | |
KR20130134532A (en) | Multilayer liquid crystal vesicle for relieving skin irritation and for recovering skin barrier, and cosmetic composition comprising the same | |
KR102333531B1 (en) | Cosmetic composition for improving skin barrier comprising high content of beta-sitosterol | |
JP5863230B2 (en) | Liposomes encapsulating oxazolidin-2-one compounds | |
EP1863435B1 (en) | Enhanced delivery of skin benefit agents | |
EP2769709B1 (en) | Pseudolipid complex mixture and a skin external application composition containing same | |
US11826468B2 (en) | Insoluble active substance carrier comprising transfersome | |
US20030017183A1 (en) | Dermatological suspensions(micro-matrix) | |
EP2072032B1 (en) | Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor | |
JP3251635B2 (en) | External preparation for skin | |
US20150119427A1 (en) | Waterborne topical compositions for the delivery of azelaic acid for treatment of skin conditions such as acne vulgaris, rosacea, seborrheic dermatitis | |
JP3827259B2 (en) | Keratinization promoter | |
KR102543029B1 (en) | Adhesive type transparent wound covering materials for preventing and improving an atopic dermatitis and Manufacturing method thereof | |
WO2022186343A1 (en) | Topical microparticle capsule preparation and dermatological topical agent | |
CN1249678A (en) | Aqueous composition comprising biotin-contg. liposomes | |
CN114177116B (en) | Salicylic acid nano composition and preparation method and application thereof | |
WO2021235275A1 (en) | Hyaluronic acid production promotor and collagen production promotor | |
KR20090037723A (en) | Methods of using and methods of producing and liposomes entrapping atelocollagen | |
CN116600782A (en) | Type III collagen production promoter and anti-aging cosmetic | |
JP2004018508A (en) | Keratinase activity-inhibitor and skin care preparation, skin cleaner or bath liquid for foot and leg | |
CN112891232A (en) | Anti-aging cream and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081110 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AXX | Extension fees paid |
Extension state: RS Payment date: 20081110 Extension state: MK Payment date: 20081110 Extension state: BA Payment date: 20081110 Extension state: AL Payment date: 20081110 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CAIRO, MARCELLO Inventor name: PERUGINI, PAOLA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 562606 Country of ref document: AT Kind code of ref document: T Effective date: 20120715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008016382 Country of ref document: DE Effective date: 20120823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120920 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2389788 Country of ref document: ES Kind code of ref document: T3 Effective date: 20121031 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20120620 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 562606 Country of ref document: AT Kind code of ref document: T Effective date: 20120620 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Effective date: 20120620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120921 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121020 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121022 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
26N | No opposition filed |
Effective date: 20130321 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008016382 Country of ref document: DE Effective date: 20130321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120920 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130402 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130402 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080402 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20200325 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20200506 Year of fee payment: 13 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210402 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210402 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210403 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230403 Year of fee payment: 16 Ref country code: DE Payment date: 20230426 Year of fee payment: 16 Ref country code: CH Payment date: 20230502 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240328 Year of fee payment: 17 |